![US Inflation Reduction Act – key changes to Pricing & Reimbursement of medicines in the USA](https://jstindt.com/wp-content/uploads/2024/07/The-US-Inflation-Reduction-Act-.jpg)
The US Inflation Reduction Act – key changes to Pricing & Reimbursement of medicines in the USA you need to know about
The Inflation Reduction Act (IRA), signed into law in August 2022, is a piece of legislation aimed at addressing several
![Plus de 330 produits rembourses dans le cadre du programme français 2024 d'acces precoce (reimbursed french early access AAP/AAC – ex-ATU)](https://jstindt.com/wp-content/uploads/2024/06/french-early-access-program-covers-330-innovative-treatments.png)
Plus de 330 produits rembourses dans le cadre du programme français 2024 d’acces precoce (reimbursed french early access AAP/AAC – ex-ATU)
En France, les programmes d’accès précoce / compassionnel (AAP/AAC) permettent de rembourser les nouveaux médicaments avant le remboursement traditionnel, ce
![](https://jstindt.com/wp-content/uploads/2024/05/New-2024-Italian-AIFA-Commission-.webp)
New 2024 Italian AIFA Commission CSE Up and Running – Insights from First Meetings
The updated regulations are effective immediately upon their publication in Italy’s Official Journal. The new 2024 Italian AIFA Commission, known
![](https://jstindt.com/wp-content/uploads/2024/01/european-pharma-market-figures.webp)
Introducing the Joint Clinical Assessment (JCA) in the EU: Aiming to Enhance Access to Innovative Therapies but Risking to Duplicate HTA for the Industry
The Joint Clinical Assessment (JCA) process in the European Union marks a significant advancement in the evaluation of innovative therapies
![](https://jstindt.com/wp-content/uploads/2024/01/france-one-of-the-largest-eu-markets-for-pharma.webp)
Pricing and Reimbursement France – Securing Early Reimbursement Through the Early Access Programs
France’s Reimbursed Early Access Programs (EAPs) allow for reimbursement of new medicines before traditional reimbursement and even before Marketing Authorization.
![](https://jstindt.com/wp-content/uploads/2023/05/Bio-Pharma.jpg)
HAS Early Access Program: Positive Trends After Two Years
The Haute Autorité de Santé (HAS) has recently shared a two-year summary of its Early Access program. The highlights include: